Vaccines targeting the neovasculature of tumorsReport as inadecuate




Vaccines targeting the neovasculature of tumors - Download this document for free, or read online. Document in PDF available to download.

Vascular Cell

, 3:7

First Online: 08 March 2011Received: 22 November 2010Accepted: 08 March 2011

Abstract

Angiogenesis has a critical role in physiologic and disease processes. For the growth of tumors, angiogenesis must occur to carry sufficient nutrients to the tumor. In addition to growth, development of new blood vessels is necessary for invasion and metastases of the tumor. A number of strategies have been developed to inhibit tumor angiogenesis and further understanding of the interplay between tumors and angiogenesis should allow new approaches and advances in angiogenic therapy. One such promising angiogenic approach is to target and inhibit angiogenesis with vaccines. This review will discuss recent advances and future prospects in vaccines targeting aberrant angiogenesis of tumors. The strategies utilized by investigators have included whole endothelial cell vaccines as well as vaccines with defined targets on endothelial cells and pericytes of the developing tumor endothelium. To date, several promising anti-angiogenic vaccine strategies have demonstrated marked inhibition of tumor growth in pre-clinical trials with some showing no observed interference with physiologic angiogenic processes such as wound healing and fertility.

AbbreviationsbFGFbasic fibroblast growth factor

CTLcytotoxic T-lymphocyte

DCdendritic cells

FGFR-1fibroblast growth factor receptor-1

GRPgastrin-releasing peptide

GM-CSFgranulocyte macrophage-colony stimulating factor

HMW-MAAHigh Molecular Weight-Melanoma Associated Antigen

HUVECshuman umbilical vein endothelial cells

IFNinterferon

imintramuscular

ipintraperioneal

ILinterleukin

Lm-LLO-HMW-MAA Listeria monocytogenesthat contains and secretes a fragment of HMW-MAA fused to the N-terminal listeriolysin O

MHC IMajor Histocompatibility Complex I

MMP-2Matrix Metalloproteinase-2

NKNatural Killer cells

PDGFR-βplatelet derived growth factor receptor beta

TEMtumor endothelial marker

ThT helper

VEGFvascular endothelial growth factor.

Electronic supplementary materialThe online version of this article doi:10.1186-2045-824X-3-7 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Agata Matejuk - Qixin Leng - Szu-Ting Chou - Archibald J Mixson

Source: https://link.springer.com/article/10.1186/2045-824X-3-7







Related documents